How FDA Says Its KASA Plan Will Streamline Quality Reviews
Executive Summary
FDA officials described some of the work being done to advance its KASA initiative, under development to make it easier for reviewers to evaluate, and for applicants to submit, quality information in applications. They compared KASA, with its pre-populated data and drop-down menus, to tax return software.
You may also be interested in...
ICH To Add Guidance On Impurities, Viral Safety, Risk Management And Quality Overall Summary
The ICH Management Committee has endorsed four quality topics for revision in its workplan recommended by its Quality Discussion Group, including a groundbreaking new guideline covering the assessment and control of extractables and leachables of drug containers.
Providers Support FDA Quest For Public Drug Manufacturing Quality Ratings
Agency agrees with those who prescribe and buy drugs on need to incentivize quality. Except providers want it yesterday.
US FDA Gets Another Appropriations Increase In FY 2020 House Bill
Overall percentage increase is not as high as the FY 2019 spending bill, but stakeholders are happy with the proposed boost in budget authority.